Trial Profile
A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects for up to 28 Days and Subjects With Stable Asthma for 14 Days
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs RV 1729 (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors RespiVert
- 13 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Nov 2014 Planned number of patients changed from 36 to 48 according to ClinicalTrials.gov